We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Landmark Alzheimer's Prevention Trial

May 17th, 2012

Genentech, the Banner Alzheimer's Institute and the National Institutes of Health partner for first-ever study of cognitively healthy individuals

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.

The landmark trial is the first to assess the potential of a medicine to stop Alzheimer's before it starts and is the cornerstone of a new international collaborative, the Alzheimer's Prevention Initiative (API), formed to accelerate the evaluation of promising but unproven prevention therapies. The study will take place in Medellin, Colombia and will involve about 300 participants from local families that can be traced to a common descendant. The participants share a rare genetic mutation that typically triggers Alzheimer's symptoms around age 45. The study will also include a small number of individuals in the United States.

The study will involve crenezumab, a humanized monoclonal antibody, which is designed to bind to amyloid beta (Abeta), the main constituent of amyloid plaque in the brains of patients with Alzheimer's disease. Abeta is proposed to be causative in the development of the disease.

Why this trial is historic

  • The trial will study patients before they show any symptoms of cognitive decline.
  • The results may help determine if the amyloid hypothesis is correct.
  • There is significant unmet medical need within this unique patient population.

Richard Scheller discusses the trial

Watch the interview series with Genentech's Executive Vice President of Research and Early Development, Richard Scheller.


Significance and description of the trial

  • A shift in the research paradigm icon-down-arrow.png
  • Unmet medical need in a unique patient population Down arrow
  • About the amyloid hypothesis Down arrow
  • Who's participating in the study Down arrow


Related resources

People who are interested in supporting Alzheimer's prevention initiatives in the United States are encouraged to join the API's Alzheimer's Prevention Registry. The registry is a community of people interested in the possibility of participating in Alzheimer's prevention studies, now or in the future.

Richard Scheller discusses the trial

Watch the interview series with Genentech's Executive Vice President of Research and Early Development,Richard Scheller.

About Crenezumab

Follow this story